Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Breaking News, Industry

22 Jun 2023

MindMed Survives Takeover Attempt: Shareholders Reject FCM Board Candidates

MindMed shareholders have voted to elect all 6 of the company’s proposed board members — rejecting the candidates from activist investors....

By Jason Najum

Culture

19 Jun 2023

Celebrity Update: CNN & Oprah Talk Psychedelic Healing

Celebrities and major media publications continue to talk about the potential of psychedelics. Now CNN and Oprah Winfrey have joined the club....

By Jason Najum

Law & Politics

15 Jun 2023

Republican Lawmakers Introduce New Bill for Psychedelic Therapy

On Wednesday, Republican lawmakers and former military veterans spoke to the public about the benefits of psychedelic medicine and a new psychedelic therapy bill...

By Jason Najum

Science

7 Jun 2023

Study Shows New Mechanism For How Psychedelics Promote Plasticity

A study published in Nature shows potential new way for how psychedelics act on the brain and promote plasticity...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

1 Jun 2023

Compass Pathways’ COMP360 Produces 50% Long-Term Depression Remission in Cancer Patients

Late last week we received news that Compass Pathways' psilocybin compound COMP360 produced extremely positive results in alleviating depression results in cancer patients....

By Jason Najum

Breaking News

25 May 2023

MindMed Publishes Report by FDA Experts: Is FCM’s Takeover Attempt Over?

A group of activist investors are trying to take control of MindMed’s board of directors. Today, MindMed has pushed back, potentially dealing a final blow to this increasingly suspect attempted...

By Jason Najum

Industry

11 May 2023

$3,500: The Cost of Treatment in America’s First Legal Psilocybin Center

Oregon has just opened the US's first licensed treatment center. Prices hit $3,500 per treatment. This is a first look at the financial realities facing providers and patients....

By Jason Najum

Industry

3 May 2023

MindMed Drama: Freemans Attempt Board of Directors Takeover

The drama continues at MindMed. The (former?) fan-favorite has had a rough run, facing an industry-wide drop in share price while dealing with a string of scenarios that have (rightly...

By Jason Najum

Science

28 Apr 2023

atai Life Sciences Presents Phase 1 Study Data on GRX-917

Earlier this year, atai Life Science company GABA Therapeutics announced Positive Final Results from Phase 1 trial of GRX-917....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.